1,673 material Form 8-K filings that 1,260 companies we cover made with the SEC in February 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Archrock reported fourth-quarter 2025 revenue of $377.1 million and net income of $116.8 million, both up from the fourth quarter of 2024, and gave 2026 guidance with net income of $306 million to $356 million and adjusted EBITDA of $865 million to $915 million. The fourth quarter included $22.9 million of sales and use tax benefits and $31.6 million of net asset sale gains that the company said were not in its 2025 guidance.
Q4 2025 revenue was $377.1 million versus $326.4 million in Q4 2024; net income was $116.8 million and EPS was $0.67 versus $0.34.
Q4 results included a $22.9 million cash net benefit from prior period sales and use tax audit settlements and $31.6 million of net gains from asset sales.
Excluding those items, full-year 2025 adjusted EBITDA would have been $846.4 million, against prior guidance of $835 million to $850 million.
The board approved an additional $100 million share repurchase authorization, with $117.7 million of capacity available as of December 31, 2025.
Avista Corp. reported 2025 net income based on GAAP of $193 million, or $2.38 per diluted share, up from $180 million, or $2.29, in 2024, and non-GAAP utility earnings of $207 million, or $2.55 per diluted share, up from $187 million, or $2.38. It initiated 2026 non-GAAP utility earnings guidance of $2.52 to $2.72 per diluted share, which reflects a $0.12 decrease from a large industrial customer's notice that it will return to procuring power independently sooner than expected. The company also said a late-December Washington order on its exit from Colstrip negatively affected 2025 utility earnings.
Full-year 2025 non-GAAP utility earnings were $207 million, or $2.55 per diluted share, versus $187 million, or $2.38, in 2024.
Full-year 2025 GAAP net income was $193 million, or $2.38 per diluted share, versus $180 million, or $2.29, in 2024.
Fourth-quarter 2025 non-GAAP utility earnings were $72 million, or $0.88 per diluted share, versus $0.89 in the fourth quarter of 2024.
2026 non-GAAP utility earnings guidance is $2.52 to $2.72 per diluted share, reflecting a $0.12 decrease from a large industrial customer's departure.
LifeStance reported fourth-quarter 2025 revenue of $382.2 million, up 17%, and net income of $11.7 million, compared with a net loss a year earlier, and issued 2026 guidance for revenue of $1.615 billion to $1.655 billion. The Board also approved a share repurchase program of up to $100 million and announced that Executive Chairman Kenneth Burdick will become non-executive Chairman effective March 16, 2026.
Q4 2025 revenue was $382.2 million, up 17%; full year revenue was $1,424.3 million, up 14%.
Q4 2025 net income was $11.7 million, versus a net loss of $7.1 million in Q4 2024; full year net income was $9.7 million.
2026 guidance: revenue of $1.615 billion to $1.655 billion and Adjusted EBITDA of $185 million to $205 million.
Board approved a repurchase program of up to $100 million of common stock; Kenneth Burdick moves to non-executive Chairman effective March 16, 2026.
Talos Energy reported a fourth-quarter 2025 net loss attributable to the company of $202.6 million, or $1.19 per diluted share, on total revenues of $392.2 million. The loss includes a $170.4 million non-cash ceiling test impairment, which the company says does not affect cash flows. The company also issued 2026 guidance calling for production of 85 to 90 thousand barrels of oil equivalent per day and capital expenditures of $500 million to $550 million.
Q4 2025 total revenues were $392.2 million; net loss was $202.6 million, or $1.19 per diluted share
Adjusted net loss was $76.5 million, or $0.44 per diluted share, for the quarter
Full-year 2025 net loss was $494.3 million, or $2.82 per diluted share; full-year revenues were $1,780.1 million
2026 guidance: production of 85 to 90 MBoe/d and capital expenditures of $500 million to $550 million
Arcosa agreed to sell all shares of Arcosa Marine Products, Inc., its barge business, to ACMP Buyer, LLC, an affiliate of Wynnchurch Capital, for about $450 million in cash, subject to customary adjustments. The company said it intends to use the net after-tax proceeds to invest in its core growth platforms and reduce debt. The barge business reported 2025 revenue of $383 million and Adjusted Segment EBITDA of $68 million, and closing depends on regulatory approval.
Price: about $450 million in cash, subject to customary purchase price adjustments
Expected close in the second quarter of 2026, subject to HSR waiting period expiration and absence of legal restraints
Either party may terminate if the deal has not closed by June 24, 2026, subject to extensions; no financing condition
Barge business 2025 revenue of $383 million and Adjusted Segment EBITDA of $68 million, reported within Transportation Products
Par Pacific reported fourth-quarter 2025 net income attributable to stockholders of $77.7 million, or $1.53 per diluted share, compared with a net loss of $55.7 million in the same quarter of 2024. For the full year, net income was $369.4 million, or $7.16 per diluted share, versus a net loss of $33.3 million in 2024, while full-year revenue declined to $7.46 billion from $7.97 billion. The company also repurchased 6.5 million shares in 2025, reducing shares outstanding by 10%, and its board authorized a new $250 million repurchase program in February 2026.
Q4 2025 net income attributable to stockholders was $77.7 million ($1.53 per diluted share), versus a $55.7 million loss in Q4 2024.
Full-year 2025 net income was $369.4 million ($7.16 per diluted share), versus a $33.3 million loss in 2024.
Full-year 2025 Adjusted EBITDA was $633.5 million, compared with $238.7 million in 2024.
Full-year 2025 revenue was $7.46 billion, down from $7.97 billion in 2024; Q4 revenue was $1.81 billion, down from $1.83 billion.
Interparfums reported record fourth-quarter and full-year 2025 results, with full-year net sales of $1.49 billion (up 2%) and diluted EPS of $5.24 (up from $5.12). The company reaffirmed its 2026 outlook of $1.48 billion in sales and $4.85 in EPS and kept its annual dividend at $3.20 per share, but said it may revisit guidance later in 2026.
Fourth-quarter 2025 net sales rose 7% to $386 million and diluted EPS rose 16% to $0.88, while operating income fell 24% to $28 million.
Full-year 2025 operating income was $270 million, down 2% from $275 million, with operating margin of 18.2% versus 18.9%.
2026 guidance is $1.48 billion in sales and $4.85 EPS, unchanged; the company will monitor early-2026 developments before potentially revisiting it.
The Board approved a 2026 annual cash dividend of $3.20 per share, unchanged from 2025; the next $0.80 quarterly dividend is payable March 31, 2026.
Concentrix issued and sold $600 million of 6.500% Senior Notes due March 1, 2029, in a registered public offering on February 24, 2026. The company said it used the proceeds with other available funds to redeem $600 million of its 6.650% Senior Notes due August 2, 2026, which had $800 million outstanding before the redemption. The filing describes a refinancing of existing debt; it does not state a change in total borrowing.
Notes carry a 6.500% rate, paid semi-annually from September 1, 2026, maturing March 1, 2029
Proceeds plus other funds used to redeem $600 million of 6.650% notes due August 2, 2026, with $800 million previously outstanding
Rate can adjust if Moody's, S&P or Fitch downgrade or later upgrade the notes' rating
Notes are redeemable before February 1, 2029 at the greater of par or a make-whole price
Paloma Acquisition Corp I, a blank check company, closed its initial public offering of 15,000,000 units at $10.00 per unit, for gross proceeds of $150 million, on February 20, 2026. A total of $150 million from the offering and a $5 million private placement was placed in a U.S.-based trust account, which is not released until a business combination is completed or public shares are redeemed, and the company has 24 months from the IPO closing to complete one.
15,000,000 units sold at $10.00 each, generating $150 million in gross proceeds; closed February 20, 2026.
Private placement of 500,000 units at $10.00 each ($5 million), with 350,000 units sold to the Sponsor and 150,000 units to Jefferies.
$150 million placed in a trust account maintained by Efficiency INC.; funds are not released until a business combination, or redemption if none is completed within 24 months of the IPO closing.
James Askew, Richard Munson and Effie Simanikas were appointed independent directors on February 18, 2026, in connection with the IPO.
W. P. Carey completed a €1.0 billion offering of senior unsecured notes on February 24, 2026, in two €500 million tranches maturing in 2031 and 2035. The company said it will use the net proceeds to repay its €500 million 2.250% notes due April 2026 and for general corporate purposes, including repaying other debt such as amounts under its $2.0 billion revolving credit facility. The filing also reports that underwriters fully exercised the option on the February 2026 common stock offering, adding $64.8 million for total gross proceeds of $496.8 million.
€500 million of 3.250% Senior Notes due October 2, 2031, and €500 million of 3.750% Senior Notes due May 10, 2035, both issued February 24, 2026
Proceeds will repay all €500 million of 2.250% Senior Notes due April 2026, plus other debt including the $2.0 billion revolver and a €215 million term loan due February 2028
Underwriters exercised in full the 900,000-share option on the common stock offering at $71.38 per share, adding $64.8 million for total gross proceeds of $496.8 million
UFP Technologies and customer Intuitive Surgical signed Amendment No. 27 to their manufacturing supply agreement on February 19, 2026, effective January 1, 2026. The amendment extends the agreement by two years through December 31, 2029, raises annual minimum volumes for the largest program in 2028 and 2029, and adds a new program, which points to a longer and larger commitment from a key medical customer.
Amendment No. 27 signed February 19, 2026 and effective January 1, 2026
Agreement term extended two years, through December 31, 2029
Annual minimum volumes for the largest program increased for 2028 and 2029; an additional program added
Volume-based pricing and cost-sharing provisions added; dollar amounts not disclosed in the filing
UFP Technologies disclosed a material cybersecurity incident after detecting suspicious activity in its IT systems on or about February 14, 2026. The company says the attacker has been removed, access has been restored in all material respects, and operations have continued in all material respects, though some data appears to have been stolen or destroyed and the investigation into personal information is ongoing. The company expects a significant portion of direct response costs to be reimbursed by insurance and does not believe the incident is reasonably likely to materially affect its financial condition or results of operations.
Suspicious activity detected on or about February 14, 2026; affected billing and label making for customer deliveries
Company says the third party has been removed and access restored in all material respects
Certain company data appears stolen or destroyed; investigation into personal information and required notifications is ongoing
Company expects a significant portion of direct response costs to be covered by insurance recoveries
UFP Technologies reported fiscal 2025 net sales of $602.8 million, up 19.5%, and GAAP diluted EPS of $8.75, up from $7.58. Fourth-quarter results were weaker: sales rose 3.4% to $148.9 million, but operating income fell 3.4% and adjusted EPS slipped to $2.44 from $2.46. Shareholders should note that the company attributed about $6.3 million of labor-related inefficiencies at its Illinois facility to 2025 results.
Full-year 2025 net income was $68.3 million, up 15.8%, and adjusted EPS was $9.76 versus $8.68 in 2024.
Fourth-quarter 2025 sales were $148.9 million, up 3.4%, with organic sales essentially flat; gross margin fell to 28.2% from 29.2%.
Full-year organic growth was approximately 1.5%, while acquisitions contributed $90.7 million of 2025 net sales.
Long-term debt fell to $123.0 million at December 31, 2025, from $176.9 million a year earlier.
Boyd Gaming disclosed that Chief Administrative Officer Stephen Thompson intends to retire effective March 31, 2026, having announced the decision on February 19, 2026. The filing says he is leaving for personal reasons and not due to any disagreement with the company, and it does not name a successor.
Stephen Thompson, Chief Administrative Officer since December 2023, announced his retirement on February 19, 2026.
Retirement is effective March 31, 2026.
The company states the departure is for personal reasons and not due to any disagreement.
Benchmark Electronics signed an employment agreement with David Moezidis, who will become President and Chief Executive Officer on March 31, 2026, and is expected to join the board as a director. The agreement sets a $900,000 base salary, equity awards and severance terms, which are detailed in the filing.
Effective date of employment as President and CEO is March 31, 2026; agreement dated February 19, 2026
Annual base salary of $900,000 with target cash bonus of 115% and maximum of 200% of base salary
Equity awards of $2,500,000 in February 2026 plus $1,500,000 on the effective date, split 50% restricted stock units and 50% performance stock units
Severance without cause or for good reason is two times the Total Cash Amount plus a pro rata bonus; three times within 24 months after a change in control
Solaris reported fourth quarter 2025 revenue of $180 million, up 8% from the third quarter, and a net loss of $4 million, or $(0.04) per diluted Class A share, which included a $41 million loss on debt extinguishment. The company raised its first quarter 2026 Adjusted EBITDA guidance to $72-77 million and set second quarter guidance at $76-84 million. For shareholders, higher revenue and raised guidance are offset by a GAAP net loss driven by the debt charge.
Fourth quarter 2025 revenue of $180 million, up 8% sequentially and up from $96 million in fourth quarter 2024.
Net loss of $4 million, or $(0.04) per diluted Class A share, including a $41 million loss on extinguishment of the Term Loan.
Adjusted pro forma earnings of $0.35 per fully diluted share, compared with $0.12 a year earlier.
First quarter 2026 Adjusted EBITDA guidance raised to $72-77 million from $70-75 million; second quarter guidance set at $76-84 million.
Shake Shack's board designated Peter Herpich, its Corporate Controller, as interim principal financial officer on February 23, 2026, while the company searches for a new chief financial officer. The change follows the November 2025 resignation of CFO Katherine Fogertey, who will serve as a Senior Advisor until March 4, 2026. The filing is a leadership change in the finance function, and it does not report any change to financial results or guidance.
Peter Herpich, age 55, designated interim principal financial officer on February 23, 2026
Katherine Fogertey resigned as CFO in November 2025 and will serve as Senior Advisor until March 4, 2026
Company has commenced a search for a new Chief Financial Officer
Herpich joined Shake Shack in May 2023 and previously held controller roles at Casper Inc. and Barnes & Noble, Inc.
Disney terminated the employment of Senior Executive Vice President and Chief Communications Officer Kristina Schake without cause, effective March 19, 2026, according to the 8-K. The company's press release says her departure coincides with the end of Bob Iger's tenure as CEO, and that Josh D'Amaro is the selected next CEO. Shareholders should note that a successor has not yet been named.
Termination decided February 20, 2026; effective March 19, 2026 per the 8-K
Press release says Schake departs after March 18, 2026, as Bob Iger's CEO tenure ends
Separation benefits follow her previously disclosed employment agreement; successor to be announced at a later date
Unitil signed Amendment No. 2 to its purchase agreement for Aquarion Water Company of Massachusetts, Aquarion Water Company of New Hampshire and Abenaki Water Co., moving the agreement's termination date from February 23, 2026 to May 25, 2026. The filing also replaces Janney Montgomery Scott with Huntington Securities as an agent under the company's $50 million common stock distribution agreement.
Amendment No. 2, dated February 23, 2026, extends the purchase agreement's termination date to May 25, 2026, from February 23, 2026.
The Aquarion companies are being acquired from Aquarion Water Authority, with South Central Connecticut Regional Water Authority party to the amendment.
On February 19, 2026, Huntington Securities replaced Janney Montgomery Scott under the $50 million distribution agreement for common stock sales.
Stock sales under the distribution agreement, if any, will be made under an effective Form S-3ASR registration statement.
Everus Construction Group reported fourth-quarter 2025 revenue of $1.01 billion, up 33.1%, and net income of $55.3 million, up 60.8%, with diluted EPS of $1.08 versus $0.67 a year earlier. For full-year 2025, net income rose 40.7% to $201.8 million and diluted EPS was $3.95, but free cash flow fell to $100.0 million from $128.8 million. The company also initiated 2026 guidance for revenue of $4.1 billion to $4.2 billion and EBITDA of $320 million to $335 million.
Q4 2025 revenue of $1.01 billion, up 33.1%; E&M revenue up 44.0% to $791.6 million, T&D revenue up 6.8% to $227.7 million
Q4 2025 diluted EPS of $1.08, compared with $0.67 in Q4 2024; full-year 2025 diluted EPS of $3.95, compared with $2.81
Full-year 2025 free cash flow of $100.0 million, down from $128.8 million, mainly from higher net capital expenditures and lower operating cash flow
2026 guidance: revenue of $4.1 billion to $4.2 billion, EBITDA of $320 million to $335 million, and gross capital expenditures of $90 million to $100 million
Matador Resources reported fourth-quarter 2025 net income of $192.5 million, down from $214.5 million a year earlier, and diluted EPS of $1.55 versus $1.71, while daily production reached a company record of 211,290 BOE. The company also gave 2026 guidance calling for oil production of 122,000 to 124,000 barrels per day and total D/C/E and midstream capital spending of $1.45 billion to $1.55 billion, a reduction of about 11% from 2025.
Q4 2025 oil and natural gas revenues were $702.8 million, down from $893.9 million in Q4 2024.
Q4 2025 adjusted EPS was $0.87, compared with $1.83 in Q4 2024 and $1.36 in Q3 2025.
2026 guidance: oil production of 122,000 to 124,000 Bbl/d, about 3% above 2025 actual production of 119,723 Bbl/d.
2025 shareholder returns totaled $218.9 million, including $163.1 million in dividends and $55.8 million in share repurchases.
Sun Communities reported fourth-quarter 2025 net income attributable to common shareholders of $121.9 million, or $0.99 per diluted share, compared with a loss of $224.4 million a year earlier. Core FFO per share was $1.40 in the quarter, down slightly from $1.41, and $6.68 for the full year, down from $6.81, but the company guided 2026 Core FFO to $6.83 to $7.03 per share and raised its quarterly distribution to $1.12 from $1.04.
Q4 2025 net income attributable to common shareholders was $121.9 million, or $0.99 per diluted share, versus a $224.4 million loss, or $1.77 per share, in Q4 2024.
Core FFO per share was $1.40 for Q4 2025 and $6.68 for full-year 2025, compared with $1.41 and $6.81 in the prior-year periods.
2026 guidance projects Core FFO per share of $6.83 to $7.03 for the full year and $1.24 to $1.32 for the first quarter.
The Board approved a quarterly distribution of $1.12 per share, up $0.08 or about 8%, with the first payment expected in April 2026.
Globus Medical reported fourth-quarter 2025 worldwide net sales of $826.4 million, up 25.7%, and GAAP diluted EPS of $1.03 versus $0.19 a year earlier. The company reaffirmed 2026 revenue guidance of $3.18 to $3.22 billion and raised its non-GAAP diluted EPS guidance to $4.40 to $4.50 from $4.30 to $4.40. The sales growth includes the Nevro acquisition; the base business excluding Nevro grew 10.6% in the quarter.
Q4 2025 worldwide net sales were $826.4 million, up 25.7%; base business excluding Nevro rose 10.6%.
Q4 2025 GAAP net income was $140.6 million; GAAP diluted EPS was $1.03 versus $0.19 in Q4 2024.
2026 revenue guidance reaffirmed at $3.18 to $3.22 billion; non-GAAP diluted EPS guidance raised to $4.40 to $4.50 from $4.30 to $4.40.
MGE Energy reported fourth-quarter and full-year 2025 results on February 24, 2026, with net income rising in both periods versus 2024. Electric segment growth was driven mainly by the Darien Solar Project and the Paris Battery Energy Storage System, both of which became operational in 2025.
Full-year 2025 net income was $135.9 million, or $3.72 per diluted share, versus $120.6 million, or $3.33 per share, in 2024.
Fourth-quarter 2025 net income was $23.3 million, or 64 cents per diluted share, versus $22.0 million, or 61 cents, a year earlier.
Full-year 2025 operating revenues were $743.7 million, up from $676.9 million in 2024.
Electric segment earnings rose $11.3 million in 2025, while gas segment earnings rose $2.5 million.
HP reported fiscal 2026 first-quarter results for the period ended January 31, 2026, with net revenue of $14.4 billion, up 6.9% from a year earlier, and non-GAAP diluted EPS of $0.81, up from $0.74. GAAP diluted EPS fell slightly to $0.58 from $0.59. HP kept its annual guidance but said it currently expects results closer to the low end of the range for GAAP EPS, non-GAAP EPS and free cash flow, citing rising memory costs.
Net revenue was $14.4 billion, up 6.9% (5.2% in constant currency) from $13.5 billion a year earlier.
GAAP diluted EPS was $0.58 versus $0.59; non-GAAP diluted EPS was $0.81 versus $0.74.
Fiscal 2026 guidance is maintained at non-GAAP diluted EPS of $2.90 to $3.20 and free cash flow of $2.8 to $3.0 billion, with results expected at the lower end.
Second-quarter non-GAAP diluted EPS is estimated at $0.70 to $0.76.
EOG Resources reported fourth quarter 2025 results on February 24, 2026, with revenue of $5,638 million, up from $5,585 million a year earlier. Net income fell to $701 million, or $1.30 per diluted share, from $1,251 million, or $2.23, in the fourth quarter of 2024, largely because impairments rose to $689 million. The filing also references first quarter and full year 2026 forecasts, but the figures for those forecasts are not in the text provided.
Q4 2025 revenue was $5,638 million versus $5,585 million in Q4 2024.
Q4 2025 net income was $701 million ($1.30 diluted EPS) versus $1,251 million ($2.23) in Q4 2024.
Q4 2025 impairments were $689 million versus $276 million in Q4 2024; excluding certain impairments, adjusted net income was $1,222 million ($2.27 per share), a non-GAAP measure.
Full year 2025 net income was $4,980 million ($9.12 per diluted share) versus $6,403 million ($11.25) in 2024.
LTC Properties reported fourth-quarter 2025 total revenues of $84.3 million, up from $52.6 million a year earlier, as it shifted its portfolio toward its SHOP senior housing segment. Diluted earnings per share were $2.11 versus $0.39, helped by a $78.1 million gain on sale of real estate, while diluted Core FFO per share rose to $0.70 from $0.65. The company also introduced 2026 guidance, including full-year diluted Core FFO per share of $2.75 to $2.79.
Q4 2025 total revenues were $84.3 million, compared with $52.6 million in Q4 2024.
Diluted EPS was $2.11, compared with $0.39, including a $78.1 million gain on sale of real estate.
Diluted Core FFO per share was $0.70, compared with $0.65; diluted Nareit FFO per share was flat at $0.72.
2026 guidance: full-year diluted Core FFO per share of $2.75 to $2.79; first-quarter diluted Core FFO per share of $0.66 to $0.68.
Axon reported fourth-quarter 2025 revenue of $797 million, up 39% year over year, and set 2026 guidance of 27% to 30% revenue growth. GAAP net income fell to $3 million from $135 million a year earlier, with an operating loss of $50 million, while non-GAAP net income rose to $178 million.
Q4 2025 revenue of $797 million, up 39% year over year; Software & Services revenue of $343 million, up 40%
Operating loss of $50 million; net income of $3 million, or $0.03 per diluted share, versus $135 million a year earlier
Non-GAAP net income of $178 million, or $2.15 per diluted share, versus $168 million a year earlier
2026 outlook of 27% to 30% revenue growth and 25.5% Adjusted EBITDA margin; new 2028 target of $6 billion in annual revenue
Mosaic reported a fourth-quarter 2025 net loss of $519 million, compared with net income of $169 million a year earlier, and cited $422 million in pre-tax notable items. For full year 2025, net income rose to $541 million from $175 million and adjusted EBITDA reached $2.4 billion, up 10 percent, though the company's 2026 phosphate and potash outlook was given without a change to prior guidance figures in the filing.
Q4 2025 net loss of $519 million, or diluted EPS of $(1.64), versus net income of $169 million in Q4 2024
Full-year 2025 net income of $541 million and diluted EPS of $1.70; adjusted EBITDA of $2.4 billion, up 10 percent
Q4 2025 adjusted EBITDA of $505 million, down from $594 million; net sales of $3.0 billion versus $2.8 billion
2026 outlook includes capital expenditures of approximately $1.5 billion and potash production of approximately 9 million tonnes
Resideo Technologies reported fourth-quarter and full-year 2025 results and gave a 2026 outlook. The full-year GAAP net loss of $527 million, driven by the expense of terminating the Indemnification Agreement with Honeywell, reversed a $116 million profit in 2024, while net revenue and Adjusted EBITDA rose. Shareholders face a large 2025 loss but a 2026 outlook calling for higher revenue and Adjusted EPS than 2025.
Full-year 2025 net loss of $527 million, compared with net income of $116 million in 2024, driven by the Indemnification Agreement termination expense; diluted loss per share was $3.77.
Full-year 2025 net revenue of $7.47 billion, up 11%, and Adjusted EBITDA of $833 million, up 20%.
Fourth-quarter 2025 net income of $136 million versus $23 million a year earlier; Adjusted EPS was $0.50 versus $0.59.
2026 outlook: net revenue of $7.8 billion to $7.9 billion and Adjusted EPS of $3.00 to $3.20, compared with 2025 Adjusted EPS of $2.68.
Trex Company said CEO Bryan Fairbanks will resign as President, CEO and director effective April 28, 2026, and that Executive Vice President and COO Adam Zambanini will succeed him and join the Board that day. Fairbanks will stay on through April 27, 2026 to support the transition, then serve as a consultant. The filing reports no disagreement with the company as the reason for his departure.
Fairbanks resigns as President and CEO and as a director, effective April 28, 2026; the Board will remain at ten members.
Zambanini, 49, becomes CEO and a director; his salary rises to $900,000, and his target incentive awards increase to 110% of base salary (annual plan) and 450% (stock plan).
Fairbanks receives $16,666 per full month as a consultant during a consulting term ending April 30, 2027.
Trex announced fourth quarter and full year 2025 results in a separate release the same day, with a conference call at 4:30 p.m. ET.
Merit Medical reported fourth-quarter 2025 revenue of $393.9 million, up 11%, and non-GAAP EPS of $1.04, up 12%. For fiscal 2026 it guided to total revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, implying growth of 6% to 8% and 5% to 8%, respectively.
Q4 2025 GAAP EPS was $0.63, up from $0.46 a year earlier; non-GAAP EPS was $1.04 versus $0.93.
Full-year 2025 revenue was $1.516 billion, up 12%, and non-GAAP EPS was $3.83, up 11%.
2026 guidance: revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, excluding possible effects of trade policies and unannounced acquisitions.
Verra Mobility reported fourth quarter 2025 revenue up 16% to $257.9 million and full year revenue up 11% to $979.1 million, with full year net income of $136.6 million versus $31.4 million in 2024. Fourth quarter Adjusted EPS fell to $0.30 from $0.33, and Adjusted EBITDA margin fell to 39% from 46%, while the company guided 2026 Adjusted EBITDA of $405 million to $415 million, compared with $415.9 million in 2025.
Q4 2025 revenue was $257.9 million, up 16% from $221.5 million; Q4 net income was $18.9 million, or $0.12 per share, versus a net loss of $66.7 million in Q4 2024, which included a goodwill impairment
Full year 2025 Adjusted EPS was $1.32, up from $1.23 in 2024; Q4 Adjusted EBITDA was $101.8 million versus $102.0 million a year earlier
2026 guidance: total revenue of $1,020 million to $1,030 million, Adjusted EBITDA of $405 million to $415 million, Adjusted EPS of $1.32 to $1.38, and Free Cash Flow of $150 million to $160 million
A new five-year New York City Department of Transportation contract, effective January 1, 2026, has a total value of $998 million; the company repurchased $133.4 million of its shares in Q4 2025
Supernus reported fourth-quarter and full-year 2025 results and issued 2026 guidance in a press release furnished as Exhibit 99.1. Revenue grew, but the company swung to a net loss, driven mainly by higher selling, general and administrative expenses, including about $72.9 million of Sage acquisition-related costs in 2025. The 2026 outlook projects total revenues of $840 million to $870 million and GAAP operating earnings of $0 to $30 million.
Q4 2025 total revenues were $211.6 million, up 21% from $174.2 million; full-year 2025 revenues were $719.0 million, up 9%.
Q4 2025 net loss was $4.1 million, or $0.07 per diluted share, versus net earnings of $15.3 million, or $0.27, a year earlier; full-year net loss was $38.6 million, or $0.68 per share.
2026 guidance: total revenues of $840 million to $870 million, GAAP operating earnings of $0 to $30 million, and adjusted operating earnings (non-GAAP) of $140 million to $170 million.
ONAPGO new patient initiation resumed in the first quarter of 2026; Q4 2025 ONAPGO net sales were $8.9 million.
Cytokinetics reported fourth quarter and full year 2025 results and gave 2026 guidance, while its MYQORZO heart drug launches in the U.S. Revenue rose from a year earlier, but the net loss widened sharply as the company built out its commercial operations. The company's 2026 GAAP combined R&D and SG&A expense guidance of $830 million to $870 million signals continued heavy spending.
Q4 2025 total revenues were $17.8 million, up from $16.9 million in Q4 2024; full year 2025 revenues were $88.0 million, up from $18.5 million.
Q4 2025 net loss was $183.0 million, or $(1.50) per share, versus a $150.0 million loss, or $(1.26) per share, a year earlier; full year net loss was $785.0 million, or $(6.54) per share, versus $589.5 million, or $(5.26) per share, in 2024
Cash, cash equivalents and investments were approximately $1.22 billion at December 31, 2025, including $100 million from a Royalty Pharma loan tranche.
2026 GAAP combined R&D and SG&A expense guidance is $830 million to $870 million.
CAVA Group reported fiscal fourth-quarter 2025 revenue of $272.8 million, up 21.2%, and net income of $4.9 million, down from $78.6 million a year earlier. That prior-year figure included an $80.1 million tax benefit from releasing a valuation allowance, and adjusted net income fell to $4.9 million from $6.5 million, while adjusted EBITDA rose 2.6% to $25.8 million. The company also gave fiscal 2026 guidance for adjusted EBITDA of $176.0 million to $184.0 million.
Q4 2025 CAVA revenue rose 21.2% to $272.8 million; same restaurant sales increased 0.5%.
Q4 2025 CAVA restaurant-level profit margin was 21.4%, down 100 basis points from 22.4% a year earlier.
Full-year 2025 revenue was $1,169.3 million, up 22.5%; adjusted net income rose 26.9% to $63.7 million.
Fiscal 2026 guidance includes adjusted EBITDA of $176.0 million to $184.0 million and same restaurant sales growth of 3.0% to 5.0%.
EXL reported fourth-quarter and full-year 2025 results, with revenue and earnings per share both up year over year. The company also issued 2026 guidance calling for revenue growth of 9% to 11%, and its board authorized a $500 million share repurchase program effective February 28, 2026.
Q4 2025 revenue was $542.6 million, up 12.7% from $481.4 million a year earlier; Q4 GAAP diluted EPS was $0.38, up from $0.31.
Full-year 2025 revenue was $2.09 billion, up 13.6%; GAAP diluted EPS was $1.54, up 28.0% from $1.21.
2026 guidance: revenue of $2.275 billion to $2.315 billion and adjusted diluted EPS of $2.14 to $2.19.
Board authorized a $500 million common stock repurchase program, effective February 28, 2026, for a two-year period.
GoDaddy reported fourth-quarter 2025 revenue of $1.3 billion, up 7% year over year, and net income of $245.1 million, up 23%. For full-year 2026, the company expects revenue of $5.195 billion to $5.275 billion, about 6% growth at the midpoint, and free cash flow of approximately $1.8 billion, compared with $1.6 billion in 2025.
Q4 2025 diluted earnings per share were $1.80, versus $1.36 a year earlier.
Full-year 2025 net income was $875.0 million, down from $936.9 million, which included a one-time, non-cash tax benefit of $34.6 million in 2025 and $267.4 million in 2024.
Q1 2026 revenue is expected in the range of $1.250 billion to $1.270 billion.
Full-year 2026 NEBITDA margin is expected to be over 33%.
Trex reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1. Full-year net sales rose 2.0% to $1.2 billion, but net income fell to $190 million from $238 million, and fourth-quarter net sales declined to $161 million from $168 million. The company also gave 2026 guidance for revenue of $1.185 billion to $1.230 billion and authorized a $150 million share repurchase for the first half of 2026.
Full-year net sales rose 2.0% to $1.2 billion; full-year net income was $190 million, or $1.78 per diluted share, versus $238 million, or $2.20, in 2024.
Fourth-quarter net sales were $161 million versus $168 million a year earlier; fourth-quarter net income was $2 million, or $0.02 per diluted share.
2026 guidance: revenue of $1.185 billion to $1.230 billion and adjusted EBITDA of $315 million to $340 million.
The board authorized a $150 million share repurchase program to be executed in the first half of 2026.
Matson reported fourth-quarter 2025 net income of $143.1 million, or $4.60 per diluted share, up from $3.80 a year earlier, while consolidated revenue fell to $851.9 million from $890.3 million. The company expects first-quarter 2026 Ocean Transportation operating income of about $50 million, lower than a year earlier, and expects full-year 2026 consolidated operating income to approach the 2025 level.
Q4 2025 diluted EPS $4.60 vs. $3.80 in Q4 2024; net income $143.1 million vs. $128.0 million
Q4 2025 revenue $851.9 million vs. $890.3 million; full-year 2025 net income $444.8 million and diluted EPS $13.81
Q1 2026 Ocean Transportation operating income expected at about $50 million; consolidated operating income expected lower than $82.1 million in Q1 2025
Board declared a $0.36 per share dividend payable March 5, 2026 to holders of record on February 5, 2026
Gulfport Energy reported fourth quarter and full year 2025 results and issued 2026 operational and financial guidance on February 24, 2026. Fourth quarter net income was $132.4 million, compared with a net loss of $273.2 million a year earlier, and the company plans to repurchase more than $140 million of its common stock in the first quarter of 2026.
Q4 2025 total revenues were $398.2 million, up from $239.9 million in Q4 2024.
Full year 2025 net income was $427.8 million, compared with a net loss of $261.4 million in 2024.
2026 guidance calls for net daily production of 1.030 to 1.055 Bcfe per day and total capital expenditures of $400 million to $430 million.
The company plans to repurchase more than $140 million of common stock during the first quarter of 2026.
Corcept reported fourth quarter and full-year 2025 results with revenue up from 2024 but net income and diluted earnings per share down. The company also gave 2026 revenue guidance of $900 million to $1,000 million, and said its Cushing's syndrome business was constrained by specialty pharmacy capacity and a fourth-quarter pharmacy transition.
Full-year 2025 revenue was $761.4 million, up from $675.0 million in 2024.
Full-year 2025 net income was $99.7 million, or $0.82 diluted per share, down from $141.2 million, or $1.23 diluted per share, in 2024.
Fourth-quarter 2025 revenue was $202.1 million, up from $181.9 million; fourth-quarter net income was $24.3 million, or $0.20 diluted per share, down from $30.7 million, or $0.26.
Full-year 2026 revenue guidance is $900 million to $1,000 million; cash and investments were $532.4 million at December 31, 2025.
First Solar reported fourth quarter and full-year 2025 results, with net sales of $1.7 billion for the quarter and $5.2 billion for the year, up from $4.2 billion in 2024. The company also issued 2026 guidance calling for net sales of $4.9 billion to $5.2 billion and Adjusted EBITDA of $2.6 billion to $2.8 billion, which compares with 2025 Adjusted EBITDA of $2.36 billion shown in the filing's reconciliation.
Q4 2025 net income per diluted share was $4.84, versus $3.65 in Q4 2024; full-year 2025 diluted EPS was $14.21, versus $12.02 in 2024
2026 guidance: volume sold of 17.0 GW to 18.2 GW, net sales of $4.9 billion to $5.2 billion, and year-end net cash balance of $1.7 billion to $2.3 billion
Year-end 2025 net cash balance was $2.4 billion, helped by proceeds from sales of 2025 Section 45X tax credits
SPX Technologies reported fourth-quarter and full-year 2025 results that grew across revenue, GAAP EPS and adjusted EPS, and issued 2026 guidance calling for higher revenue, adjusted EBITDA and adjusted EPS than in 2025. For shareholders, the filing shows higher earnings in 2025 and a 2026 outlook that projects further growth, with the company citing demand, acquisitions and production capacity.
Q4 2025 revenue was $637.3 million, up 19.4%, and GAAP EPS was $1.54, up 29.4%.
Full-year 2025 revenue was $2,265.1 million, up 14.2%, and adjusted EPS was $6.76, up 21.1%.
2026 guidance: revenue of $2.535 to $2.605 billion, adjusted EBITDA of $590 to $620 million, and adjusted EPS of $7.60 to $8.00, compared with 2025 levels of $2.265 billion, $507 million and $6.76.
Realty Income reported fourth-quarter 2025 net income available to common stockholders of $296.1 million, or $0.32 per share, up from $199.6 million, or $0.23 per share, a year earlier, on total revenue of $1,487.9 million versus $1,340.3 million. The company also introduced 2026 AFFO per share guidance of $4.38 to $4.42, compared with full-year 2025 AFFO of $4.28 per share.
Q4 2025 net income per share was $0.32, compared with $0.23 in Q4 2024; AFFO per share was $1.08, compared with $1.05
Full-year 2025 AFFO per share was $4.28, compared with $4.19 in 2024
2026 guidance: net income per share of $1.65 to $1.69 and AFFO per share of $4.38 to $4.42; initial investment volume of approximately $8.0 billion
Occupancy was 98.9% at December 31, 2025, compared with 98.7% at September 30, 2025
Jazz Pharmaceuticals reported full-year 2025 total revenues of $4.3 billion, up 5%, and fourth-quarter revenues of $1.2 billion, up 10%, but its GAAP net result swung to a loss of $356 million for the year after a profit of $560 million in 2024. The company also guided to 2026 total revenues of $4.25 billion to $4.50 billion, which gives shareholders a revenue outlook while the 2025 loss was driven largely by acquired in-process R&D charges.
Full-year 2025 total revenues were $4.27 billion, up from $4.07 billion in 2024; fourth-quarter revenues were $1.20 billion, up 10%.
Full-year 2025 GAAP net loss was $356 million, or $5.84 per diluted share, compared with GAAP net income of $560 million, or $8.65 per diluted share, in 2024.
Acquired in-process R&D expense was $948 million in 2025, including $905 million for Modeyso from the Chimerix acquisition.
2026 guidance calls for total revenues of $4.25 billion to $4.50 billion.
Tanger reported fourth-quarter 2025 diluted net income of $0.29 per share, up from $0.23, and FFO of $0.63 per share, up from $0.54, with quarterly total revenues of $160.3 million versus $140.7 million a year earlier. The company also introduced full-year 2026 guidance of $2.41 to $2.49 in diluted FFO per share and $1.04 to $1.12 in diluted net income per share, and disclosed January 2026 financing transactions including $550 million of unsecured term loans.
Q4 2025 diluted net income was $0.29 per share ($33.2 million), versus $0.23 per share ($26.3 million) a year earlier
Full-year 2025 FFO was $2.33 per share ($278.0 million), versus $2.12 per share in 2024
2026 guidance: diluted FFO of $2.41 to $2.49 per share and diluted net income of $1.04 to $1.12 per share
January 2026 financing included $550 million of unsecured term loans and $250 million of 2.375% exchangeable senior notes due 2031
TransMedics reported fourth quarter 2025 revenue of $160.8 million, up 32% from a year earlier, and full year 2025 revenue of $605.5 million, up 37%. Net income was boosted by an $83.8 million tax benefit in the quarter, mainly from a one-time $103.3 million release of a deferred tax asset valuation allowance, and the company guided to 2026 revenue of $727 million to $757 million.
Q4 2025 revenue $160.8 million, up 32% from $121.6 million; net income $105.4 million, or $2.62 per diluted share, versus $0.19 a year earlier
Q4 net income includes an $83.8 million tax benefit, primarily a one-time $103.3 million valuation allowance release
Full year 2025 revenue $605.5 million, up 37%; net income $190.3 million, or $4.87 per diluted share
2026 revenue outlook of $727 million to $757 million, 20% to 25% growth; Q4 gross margin 58% versus 59% a year earlier
CoStar Group reported fiscal 2025 revenue of $3.2 billion, up 19%, and fourth-quarter revenue of $900 million, up 27%. Full-year net income fell to $7 million from $139 million in 2024, reflecting acquisition costs tied to Matterport and Domain, while Adjusted EBITDA rose 83% to $442 million. The company affirmed its 2026 revenue and Adjusted EBITDA guidance and plans to repurchase $700 million of stock in 2026.
Full-year 2025 revenue was $3.2 billion, up 19% from $2.7 billion; fourth-quarter revenue was $900 million, up 27% from $709 million.
Full-year 2025 net income was $7 million, or $0.02 per diluted share, versus $139 million, or $0.34 per diluted share, in 2024.
Full-year 2025 Adjusted EBITDA was $442 million, up 83%; full-year Adjusted EPS was $0.87 versus $0.73.
2026 guidance was affirmed: revenue of $3.78 billion to $3.82 billion and Adjusted EBITDA of $740 million to $800 million.
Workday reported fiscal fourth-quarter 2026 total revenues of $2.532 billion, up 14.5%, and GAAP diluted earnings per share of $0.55, up from $0.35 a year earlier. It also guided fiscal 2027 subscription revenues to $9.925 billion to $9.950 billion, or 12% to 13% growth, while restructuring expenses rose to $303 million for the full year from $84 million.
Q4 total revenues were $2.532 billion, up 14.5%; GAAP diluted EPS was $0.55 versus $0.35.
Fiscal 2026 total revenues were $9.552 billion, up 13.1%; GAAP operating income was $721 million versus $415 million.
Fiscal 2027 guidance: subscription revenues of $9.925 billion to $9.950 billion and non-GAAP operating margin of about 30.0%.
Co-founder Aneel Bhusri returned as chief executive officer; the company repurchased 12.8 million Class A shares for $2.9 billion in fiscal 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.